Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
L-Ascorbic acid (HB1238)
Description:Antioxidant. Enhances iPSC generation and increases reprogramming efficiency. Supports mesenchymal stem cell proliferation.
Purity:>99%
CAT335 (HB8146)
Description:K2P2.1 (TREK-1) modulator. Selectively and irreversibly activates TREK-1CG* but not wild-type K2P2.1 (TREK-1)
Purity:>98%
1-EBIO (HB1045)
Description:Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.
Purity:>98%